What the evidence actually supports — sunscreen, retinoids, exercise, sleep, and the early human work on rapamycin and metformin — versus the hype of unproven clinics, and the one celebrity longevity budget that has been said out loud.
Anti-ageing: lie or reality? The industry would like you to pick a camp before breakfast. This investigation will not. At the highest level, the honest file is split in three: a short list of interventions with real human evidence, a longer list of early science that has not earned a miracle headline, and a marketplace of supplements, drips and clinics that are running ahead of the data. Celebrities spend as if the third list were the first. The evidence does not.
What the science actually supports
Start with the boring well. Daily sunscreen is the closest thing the field has to a proven anti-photoageing habit. An Australian randomised trial of 903 adults, later widely cited in dermatology reviews, found that people assigned to daily sunscreen showed 24 per cent less measured skin ageing over four years than those who used it only when they felt like it. That is not a serum advert. It is a controlled result about ultraviolet light, the main external driver of how skin looks older than it is.
Topical retinoids, especially prescription tretinoin, are the other first-line reality. Classic randomised work, including the trials associated with Weiss and later dermatology literature, showed improvement in the fine wrinkling and roughness of photodamaged skin. Irritation is a common side effect, which is one reason this is a medical product, not a party trick. Exercise and sleep sit one layer down: they are among the best-supported habits for metabolic health, cardiovascular risk and how recovered a face looks in the morning. That is not the same sentence as “exercise reverses ageing.” Nobody serious should sell it as a time machine.
The early drugs, without the TED-Talk ending
Rapamycin is the molecule longevity Twitter treats as destiny. The mechanistic story is real: it inhibits mTOR, and in animals it is one of the more convincing lifespan extenders in the gerontology literature. The human story is early. The PEARL trial, reported in 2025, tested intermittent low-dose rapamycin in healthy middle-aged and older adults and found it was relatively safe over 48 weeks, with modest, exploratory secondary signals. It did not prove that rapamycin extends human lifespan or delivers broad “geroprotection.” Systematic reviews have said the same thing in plainer language: the human data have not established that rapamycin delays ageing or lengthens life. A small exploratory study of topical rapamycin on skin is interesting. It is not a systemic anti-ageing licence.
Metformin, the diabetes drug, has a similar gap between vibe and verdict. Observational studies in people with type 2 diabetes have reported associations with lower rates of some age-related outcomes, and the TAME trial was designed to test whether metformin can delay the accumulation of age-related disease. Observational data are confounded — people who take a drug are not a random sample — and metformin has not been proven as an anti-ageing medicine in healthy people. Anyone selling it as a general longevity prescription is ahead of the regulators and the trials.
The lie is not that ageing can be slowed in specific, measurable ways. The lie is that a clinic, a supplement stack or a celebrity protocol has already finished the science.
Hype, clinics, and one public budget
Unproven NAD boosters, “young blood,” plasma-exchange tourism, and stem-cell or IV clinics with brochures instead of randomised evidence belong on the hype side of this ledger until they produce it. Bryan Johnson, the tech entrepreneur behind Project Blueprint, is the rare longevity spender who has put a number on the record. Since 2021 he has described a highly measured personal protocol; Business Insider, Bloomberg and later profiles have reported that he has said the protocol costs about $2 million a year. He has also discussed experimenting with plasma exchange, including with his son, and later said he stopped after seeing no benefits. Netflix’s 2025 documentary Don’t Die made the project a pop product. None of that is a clinical guideline, and none of it is a reason to invent what other stars spend. If they have not published a budget, we do not print one.
The useful funnel is quieter, and it is already live. Limited Editions Europe is previewing Everyday Vitality by Richiegaps — a daily practice, not a miracle claim. MotivationsMasters has the companion philosophy in its daily vitality orientation and the 18-hour energy blueprint. For the money cut on what faces are worth, read this week’s Celebrityfees companion, Wake Up News, only at Celeb Fees: the celebrity anti-ageing spend and the looks economy, and Global Celebrity Meter’s file on insuring a face, eyes and body. A word on what this investigation will not do. We will not bless a supplement stack, an NAD infusion, a “young blood” booking, or a stem-cell weekend because a brochure used the word clinical. Some of those ideas have early lab stories. Early lab stories are not human outcome trials. Plasma exchange, which Johnson himself has discussed and then stepped back from after reporting no benefits, is a useful public example of an expensive idea meeting a personal evidence check. That is more honest than a clinic that never publishes the check.
Lifestyle is allowed to be unglamorous. Sleep, training, sunscreen, a retinoid prescribed by someone who can manage the irritation — these are the unfashionable receipts. Everyday Vitality and the MotivationsMasters vitality pages are the network’s version of that quieter discipline, not a claim that a ritual reverses a decade. If a star wants a $2 million measurement programme, that is their budget to state. If a reader wants a daily practice, the live pages are already there. This is not medical advice, and it is not a shopping list. It is the highest-level version of a simple split: sunscreen, retinoids, movement and sleep have receipts. The rest of the industry is asking you to pay as if they did too.
